Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rifampicin and pyrazinamide pharmacokinetics in shortened tuberculosis treatment
2019-003721-25Phase 2Active
- Sponsor
- Region Östergötland
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rifampicin and pyrazinamide in Tuberculosis (TB) (2 arms), sponsored by Region Östergötland. Primary endpoint: Pyrazinamide AUC0-24h. Started Dec 2019; status: active.
02
Drugs
rifampicinpyrazinamide
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on 2019-003721-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003721-25.